PEPTIDES for Veterans Act 2026: What the New Bill Could Mean for Peptide Research
The PEPTIDES for Veterans Act is a new 2026 bill that would require the Department of Veterans Affairs to review federal peptide definitions, examine existing research, study safety and efficacy, and decide whether peptide-based therapies warrant further evaluation in veterans. It does not approve any peptide or immediately create a treatment program.
Introduced on September 1, 2026, the Providing Evidence-based Peptide Therapies to Improve Delivery and Expanded Services for Veterans Act, shortened to the PEPTIDES for Veterans Act, would require the Department of Veterans Affairs (VA) to review how peptides are currently defined, assess developments in the research, and conduct a formal study of peptide-based therapies.
That sounds broad because it is. The bill does not identify BPC-157, TB-500, KPV, or any other individual research peptide. It also does not assume that peptide-based therapies work. The first step is much more fundamental: decide what belongs in the category, then examine the evidence.
Note: This content is provided for educational purposes within a research context only. It does not promote or suggest the use of peptides for personal, medical, veterinary, or other non-research applications.
What Is the PEPTIDES for Veterans Act?
H.R. 10212 is a bill introduced by Representative Nancy Mace and referred to the House Committee on Veterans’ Affairs on September 1, 2026. Its stated purpose is to direct the VA to study the potential benefits of peptide-based therapies for veterans receiving care through the Department.
The important word is study.
If the bill becomes law, the VA would not begin by providing peptide-based therapies. It would first review existing federal regulations and guidance, establish working definitions, and report those findings to Congress. Only after that would the larger safety and efficacy study begin.
That sequence makes H.R. 10212 more of a research-framework bill than an immediate access bill.
Why Does the Bill Start by Defining “Peptide”?
The bill specifically instructs the VA to review the scope of “peptide” as a defined term in federal regulations and guidance and consider developments in peptide research that have occurred since those definitions were established. The VA would then create definitions for both “peptide” and “peptide-based therapy” for purposes of the Act.
The reason becomes clearer when the category is viewed scientifically.
“Peptide” does not describe one regulatory status or one level of evidence. The category includes endogenous signaling molecules, approved peptide drugs, investigational drug candidates, synthetic analogs, and laboratory research compounds. Two molecules can both be peptides while sitting at completely different stages of pharmaceutical development.
Researchers encounter the same problem when comparing compounds across different biological systems. That breadth is especially clear across immune and neuroendocrine peptide research, where receptor targets, tissue distribution, and signaling pathways can differ substantially between compounds that still fall under the peptide label.
In other words, chemical category does not equal clinical status.
A useful federal definition therefore has to do more than describe amino-acid chains. It has to establish what the VA means when the bill later refers to a “peptide-based therapy.”
What Would Happen If H.R. 10212 Became Law?
The bill establishes a step-by-step process rather than immediately creating a VA peptide program.
| Stage | What H.R. 10212 Requires | Timing |
|---|---|---|
| Regulatory review | Review federal peptide regulations, guidance, terminology, and newer research developments | Begins after enactment |
| Definitions | Establish definitions of “peptide” and “peptide-based therapy” for the Act | Part of the initial review |
| First report | Report regulatory findings to Congress | Within 180 days of enactment |
| VA study | Review safety, efficacy, medical research, clinical protocols, and potential applications | After the initial report |
| Study completion | Submit findings on whether peptide-based therapies should be provided | Within 18 months after the first report |
| Possible pilot | Establish a voluntary pilot only if the VA study supports moving forward | Conditional on study findings |
The research areas named in the bill include recovery, rehabilitation, chronic pain, mental health, physical wellness, and other service-connected conditions affecting veterans.
Recovery is particularly broad from a research standpoint. Peptides studied in recovery research may involve angiogenic signaling, cell migration, extracellular matrix behavior, or cytoskeletal regulation rather than one shared mechanism.
The VA would also be required to review medical research and establish clinical protocols. The proposed pilot is conditional: it only follows if the VA’s study concludes that peptide-based therapies should be provided.
That distinction matters because discussion of the bill can easily jump from “Congress wants the VA to study peptides” to “the VA is going to provide peptides.” H.R. 10212 does not make that jump.
Why Is Peptide Regulation Getting More Attention in 2026?
The Veterans bill arrives during an unusually active year for federal peptide discussion. On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptide-related bulk drug substances for possible inclusion on the Section 503A Bulks List.
| Substance | Use Evaluated by FDA | Committee Outcome |
|---|---|---|
| BPC-157 | Ulcerative colitis | Recommended |
| KPV | Wound healing and inflammatory conditions | Recommended |
| TB-500 | Wound healing | Recommended |
| MOTS-c | Obesity and osteoporosis | Recommended |
| Emideltide | Opioid withdrawal, chronic insomnia, and narcolepsy | Not recommended |
| Semax | Cerebral ischemia, migraine, and trigeminal neuralgia | Recommended |
| Epitalon | Insomnia | Recommended |
These were the particular uses considered during the compounding review. They are not FDA-approved indications for these compounds. The committee recommended six of the seven peptide-related substances: BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. Emideltide did not receive a favorable recommendation.
That timing does not mean the July FDA process and H.R. 10212 are part of the same initiative. They are not.
What it does show is that peptide terminology, evidence quality, compounding policy, and clinical translation are receiving federal attention at the same time.
The FDA Peptide Vote and the Veterans Bill Are Two Different Processes
The July FDA meeting concerned whether particular bulk drug substances should be recommended for possible inclusion on the 503A Bulks List. The PEPTIDES for Veterans Act concerns a proposed VA regulatory review, research study, and potentially a later pilot program.
Neither process is equivalent to FDA drug approval.
FDA advisory committees provide independent expert advice to the agency. Their recommendations are non-binding, meaning the agency considers the committee’s vote but remains responsible for the regulatory decision.
The 503A framework is also its own regulatory pathway. Under current FDA rules, qualifying compounders may use certain bulk drug substances when specific statutory conditions are met. A substance being considered for that list is not the same as a drug being approved after a complete FDA review of safety, efficacy, manufacturing, and labeling.
In simple terms:
research interest → regulatory review → clinical investigation → compounding consideration → drug approval
Those stages can interact, but they are not interchangeable.
Where Does BPC-157 Fit Into This Research Picture?
BPC-157 is a useful example because it shows why increased federal interest does not remove the normal evidence hierarchy. More than three decades of preclinical research have examined BPC-157 across gastrointestinal, musculoskeletal, cardiovascular, and neurological models. Yet substantial pharmaceutical-development questions remain.
This gap helps explain why BPC-157 still has no approved formulation despite more than three decades of experimental research. A 2026 review in Pharmaceutics identified missing formulation work, limited human pharmacokinetic information, incomplete permeability characterization, and a lack of standardized pharmaceutical preparations.
The issue is therefore more complicated than asking whether a biological effect has appeared in an experimental model.
Researchers also need to know how a compound behaves as a pharmaceutical substance: how stable it is, how quickly it is cleared, how exposure relates to downstream biological activity, whether analytical methods can measure it reliably, and whether findings reproduce across independent models.
Peptide half-life research illustrates one part of that problem. A compound can fall rapidly in measurable concentration while downstream signaling persists, so pharmacokinetics and biological response cannot automatically be treated as the same curve.
The BPC-157 evidence base is also changing. A randomized, double-blind, placebo-controlled Phase 2 study registered in 2026 is currently recruiting participants with acute grade II hamstring strains. The study has an estimated enrollment of 120 participants and compares investigational BPC-157 with placebo alongside standardized rehabilitation.
No results have been posted. That means two statements can currently be true at the same time: BPC-157 has attracted substantial research interest, and controlled human evidence remains incomplete.
The distinction is equally important when comparing BPC-157 and TB-500 in research. The compounds appear in overlapping recovery-related discussions, but different mechanisms and development requirements mean evidence from one cannot substitute for evidence on the other.
What the PEPTIDES for Veterans Act Does Not Do
The easiest way to understand the current status is to separate what has been proposed from what has actually changed.
H.R. 10212 does not:
- FDA-approve BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, or another research peptide
- Name any specific peptide that the VA must study
- Immediately make peptide-based therapies available through the VA
- Turn the July PCAC recommendations into final FDA decisions
- Establish clinical safety or efficacy for an individual compound
- Change the research-use status of materials in our research catalog
That last point remains important. BioHub products are supplied for research, laboratory, and analytical purposes only. They are not intended for human or veterinary use, and BioHub Peptides is not a Section 503A compounding pharmacy or a Section 503B outsourcing facility.
Research use only is still the boundary. Federal interest in a compound does not make that boundary disappear.
Where the PEPTIDES for Veterans Act Stands Today
As of September 4, 2026, H.R. 10212 has been introduced in the House and referred to the Committee on Veterans’ Affairs. It has not been enacted into law. If it advances, the first scientifically interesting output may not be a peptide study at all. It may be the VA’s definition of what qualifies as a peptide and a peptide-based therapy under the Act.
From there, the evidence becomes the important part: which compounds fall within the scope, what data exist, whether those data are preclinical or human, what safety information is available, whether formulations are standardized, and whether controlled research supports moving further.
That is a more useful way to follow H.R. 10212 than treating federal attention itself as evidence.
Peptide research is moving quickly in 2026. The standards used to interpret it still matter just as much.
Research References
- U.S. Congress. Providing Evidence-based Peptide Therapies to Improve Delivery and Expanded Services for Veterans Act. H.R. 10212, 119th Congress. Introduced September 1, 2026.
- U.S. Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee.
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act.
- Mateescu DM, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026;18(5):625.
- ClinicalTrials.gov. BPC 157 for Acute Hamstring Muscle Strain Repair (BPC-HAMSTR). NCT07437547.
Frequently Asked Questions
The PEPTIDES for Veterans Act, H.R. 10212, is a proposed 2026 bill directing the Department of Veterans Affairs to review federal peptide definitions and regulations, study the safety and efficacy of peptide-based therapies, and determine whether further VA evaluation is warranted.
No. As of September 4, 2026, H.R. 10212 has been introduced in the House and referred to the House Committee on Veterans' Affairs. It has not been enacted into law.
No. The introduced bill does not name BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, or another individual peptide. It requires the VA to establish definitions and then conduct a broader study of peptide-based therapies.
No. The FDA's Pharmacy Compounding Advisory Committee recommended six peptide-related bulk substances for possible inclusion on the Section 503A Bulks List. Advisory committee recommendations are non-binding, and the July meeting was not an FDA drug-approval proceeding.
Peptides span a broad scientific category that includes approved medicines, investigational drug candidates, endogenous signaling molecules, synthetic analogs, and research compounds. The definition established by the VA would determine what falls within the scope of the Act's later study and possible pilot program.
"*" indicates required fields